Literature DB >> 34040312

Obstructive Jaundice: An Unusual Presentation of Neuroendocrine Differentiation in Prostatic Adenocarcinoma.

Sampath Santhosh1, Godwin Jeeva1, Ranjan Kumar Mohapatra2.   

Abstract

An elderly male on androgen deprivation therapy for prostatic adenocarcinoma presented with obstructive jaundice. Since biopsy from the head of the pancreas showed neuroendocrine carcinoma (NEC), he was diagnosed with second primary pancreatic NEC. Ga-68 DOTANOC positron emission tomography/computed tomography (PET/CT) done subsequently showed enlarged mildly DOTANOC-avid retroperitoneal nodes infiltrating the pancreas. These nodes were found to be progression of prostate-specific membrane antigen (PSMA) nonavid retroperitoneal nodes visualized in his Ga-68 PSMA PET/CT performed at another institution before 4 months, when there was no lesion in the pancreas. This observation revised the diagnosis from second primary pancreatic NEC to progression of neuroendocrine differentiation in preexisting prostatic adenocarcinoma. Copyright:
© 2021 Indian Journal of Nuclear Medicine.

Entities:  

Keywords:  Ga-68 DOTANOC; Ga-68 prostate-specific membrane antigen; jaundice; neuroendocrine differentiation; positron emission tomography/computed tomography; prostatic adenocarcinoma

Year:  2021        PMID: 34040312      PMCID: PMC8130684          DOI: 10.4103/ijnm.IJNM_127_20

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


  8 in total

1.  Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus 68Ga-DOTA NOC PET-CT.

Authors:  Sharjeel Usmani; Najeeb Ahmed; Fahad Marafi; Rashid Rasheed; Henney G Amanguno; Fareeda Al Kandari
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

2.  Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.

Authors:  Partha Sarathi Chakraborty; Madhavi Tripathi; Krishan Kant Agarwal; Rajeev Kumar; Maneesh Kumar Vijay; Chandrasekhar Bal
Journal:  Clin Nucl Med       Date:  2015-02       Impact factor: 7.794

3.  177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.

Authors:  Majid Assadi; Elahe Pirayesh; Seyed Javad Rekabpour; Farshad Zohrabi; Esmail Jafari; Iraj Nabipour; Abdolhamid Esmaili; Abdullatif Amini; Hojjat Ahmadzadehfar
Journal:  Clin Nucl Med       Date:  2019-12       Impact factor: 7.794

4.  18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.

Authors:  Emine Acar; Gamze Çapa Kaya
Journal:  Clin Nucl Med       Date:  2019-01       Impact factor: 7.794

5.  68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation.

Authors:  Sirong Chen; Shing Kee Cheung; Ka-Nin Wong; Kwok Kee Wong; Chi-Lai Ho
Journal:  Clin Nucl Med       Date:  2016-12       Impact factor: 7.794

Review 6.  Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Mattia Riondato; Andrea Ciarmiello
Journal:  Curr Radiopharm       Date:  2017

Review 7.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

8.  Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.

Authors:  Girish Kumar Parida; Sarthak Tripathy; Shreya Datta Gupta; Abhinav Singhal; Rakesh Kumar; Chandrasekhar Bal; Shamim Ahmed Shamim
Journal:  Clin Nucl Med       Date:  2018-04       Impact factor: 7.794

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.